Pretransplantation CMV-specific T cells protect recipients of T-cell-depleted grafts against CMV-related complications

Blood

Volumn 107, Issue 1, 2006, Pages 389-396

  Chalandon, Yves ^b   Degermann, Sylvie ^b   Villard, Jean ^b   Arlettaz, Lionel ^b   Kaiser, Laurent ^b   Vischer, Solange ^b   Walter, Steffen ^b   Heemskerk, Mirjam H M ^b   Van Lier, Rene A W ^b   Helg, Claudine ^b   Chapuis, Bernard ^b   Roosnek, Eddy ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLOOD; CELL SURVIVAL; CELL TRANSPLANTATION; COHORT ANALYSIS; CYTOMEGALOVIRUS; CYTOTOXIC T LYMPHOCYTE; DONOR; HUMAN; IMMUNE STATUS; IMMUNITY; INFECTION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRANSPLANTATION;

EID: 30144436538     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-07-2746     Document Type: Article

References (48)

1. Ljungman P, Engelhard D, Link H, et al. Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: experience of European Bone Marrow Transplant Group. Clin Infect Dis. 1992;14:831-835.
2. Ljungman P, Brand R, Einsele H, et al. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood. 2003;102:4255-4260.
3. Quinnan GV Jr, Kirmani N, Rook AH, et al. Cytotoxic T cells in cytomegalovirus infection: HLArestricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N Engl J Med. 1982;307:7-13.
4. Reusser P, Riddell SR, Meyers JD, Greenberg PD. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood. 1991;78:1373-1380.
5. Li C-R, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood. 1994;83:1971-1979.
6. Gratama JW, van Esser JW, Lamers CH, et al. Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8(+) T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood. 2001;98:1358-1364.
7. Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood. 2002;99:3916-3922.
8. Cwynarski K, Ainsworth J, Cobbold M, et al. Direct visualization of cytomegalovirus-specific Tcell reconstitution after allogeneic stem cell transplantation. Blood. 2001;97:1232-1240.
9. Montagna D, Locatelli F, Moretta A, et al. T lymphocytes of recipient origin may contribute to the recovery of specific immune response towards viruses and fungi in children given cord blood transplantation. Blood. 2004;103:4322-4329.
10. Mackall CL, Fleisher TA, Brown MR, et al. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med. 1995;332:143-149.
11. Hakim FT, Cepeda R, Kaimei S, et al. Constraints on CD4 recovery postchemotherapy in adults: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells. Blood. 1997;90:3789-3798.
12. Dumont-Girard F, Roux E, Van Lier RA, et al. Reconstitution of the T cell compartment after bone marrow transplantation: restoration of the repertoire by thymic emigrants. Blood. 1998;92:4464-4471.
13. Roux E, Dumont-Girard F, Starobinski M, et al. Recovery of immune reactivity after T cell depleted bone marrow transplantation depends on thymic activity. Blood. 2000;96:2299-2303.
14. Roux E, Helg C, Chapuis B, Jeannet M, Roosnek E. Evolution of mixed chimerism after allogeneic bone marrow transplantation as determined on granulocytes and mononuclear cells by the polymerase chain reaction. Blood. 1992;79:2775-2781.
15. Roux E, Abdi K, Speiser D, et al. Characterization of mixed chimerism in patients with chronic myeloid leukemia transplanted with T-cell-depleted bone marrow: involvement of different hematologic lineages before and after relapse. Blood. 1993;81:243-248.
16. Nastke MD, Herrgen L, Walter S, et al. Major contribution of codominant CD8 and CD4 T cell epitopes to the human cytomegalovirus-specific T cell repertoire. Cell Mol Life Sci. 2005;62:77-86.
17. Chalandon Y, Vischer S, Helg C, Chapuis B, Roosnek E. Quantitative analysis of chimerism after allogeneic stem cell transplantation by PCR amplification of microsatellite markers and capillary electrophoresis with fluorescence detection: the Geneva experience. Leukemia. 2003;17:228-231.
18. Kaiser L, Perrin L, Kolarova L, et al. Improved detection of CMV infection after allogeneic hematopoietic stem cell transplantation using an ultrasensitive plasma DNA PCR. J Clin Microbiol. 2002;40:4251-4255.
19. Hadaya K, Wunderli W, Deffernez C, et al. Monitoring of cytomegalovirus infection in solid-organ transplant recipients by an ultrasensitive plasma PCR assay. J Clin Microbiol. 2003;41:3757-3764.
20. Heemskerk MH, Hoogeboom M, Hagedoorn R, et al. Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer. J Exp Med. 2004;199:885-894.
21. Bieri S, Helg C, Chapuis B, Miralbell R. Total body irradiation before allogeneic bone marrow transplantation: is more dose better? Int J Radiat Oncol Biol Phys. 2001;49:1071-1077.
22. Hale G, Zhang MJ, Bunjes D, et al. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood. 1998;92:4581-4590.
23. Kottaridis PD, Milligan DW, Chopra R, et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood. 2000;96:2419-2425.
24. Gamadia LE, Rentenaar RJ, Baars PA, et al. Differentiation of cytomegalovirus-specific CD8(+) T cells in healthy and immunosuppressed virus carriers. Blood. 2001;98:754-761.
25. + T cells. Blood. 2002;100:3690-3697.
26. Gandhi MK, Wills MR, Okecha G, et al. Late diversification in the clonal composition of human cytomegalovirus-specific CD8+ T-cells following allogeneic haemopoietic stem cell transplantation. Blood. 2003;102:3427-3438.
27. Roux E, Helg C, Dumont-Girard F, et al. Analysis of T cell repopulation after allogeneic bone marrow transplantation: significant differences between recipients of T cell depleted and unmanipulated grafts. Blood. 1996;87:3984-3992.
28. Mackall CL, Bare CV, Granger LA, et al. Thymic-independent T cell regeneration occurs via antigen-driven expansion of peripheral T cells resulting in a repertoire that is limited in diversity and prone to skewing. J Immunol. 1996;156:4609-4616.
29. Dietrich PY, Caignard A, Lim A, et al. In vivo T-cell clonal amplification at time of acute graft-versus-host disease. Blood. 1994;84:2815-2820.
30. Brochu S, Baron C, Hétu F, Roy DC, Perreault C. Oligoclonal expansion of CTLs directed against a restricted number of dominant minor histocompatibility antigens in hemopoietic chimeras. J Immunol. 1995;155:5104-5114.
31. Dolstra H, Van de Wiel-van Kemenade E, De Witte T, Preijers F. Clonal predominance of cytomegalovirus-specific CD8+ cytotoxic T lymphocytes in bone marrow recipients. Bone Marrow Transplant. 1996;18:339-345.
32. Gorski J, Yassai M, Zhu X, et al. Circulating T cell repertoire complexity in normal individuals and bone marrow recipients analyzed by CDR3 size spectratyping: correlation with immune status. J Immunol. 1994;152:5109-5119.
33. Witherspoon RP, Lum LG, Storb R. Immunologic reconstitution after human marrow grafting. Semin Hematol. 1984;21:2-10.
34. Storek J, Gooley T, Witherspoon RP, Sullivan KM, Storb R. Infectious morbidity in long-term survivors of allogeneic marrow transplantation is associated with low CD4 T cell counts. Am J Hematol. 1997;54:131-138.
35. Lucas KG, Small TN, Heller G, Dupont B, O'Reilly RJ. The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation. Blood. 1996;87:2594-2603.
36. Wang FZ, Dahl H, Linde A, et al. Lymphotropic herpesviruses in allogeneic bone marrow transplantation. Blood. 1996;88:3615-3620.
37. Socie G, Stone JV, Wingard JR, et al. Long-term survival and late deaths after allogeneic bone marrow transplantation: Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med. 1999;341:14-21.
38. Godthelp BC, van Tol MJ, Vossen JM, van Den Elsen PJ. T-cell immune reconstitution in pediatric leukemia patients after allogeneic bone marrow transplantation with T-cell-depleted or unmanipulated grafts: evaluation of overall and antigen-specific T-cell repertoires. Blood. 1999;94:4358-4369.
39. Kroger N, Zabelina T, Kruger W, et al. Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion with antithymocyte globulin. Br J Haematol. 2001;113:1060-1071.
40. Craddock C, Szydlo RM, Dazzi F, et al. Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis. Br J Haematol. 2001;112:228-236.
41. Chakrabarti S, Mackinnon S, Chopra R, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood. 2002;99:4357-4363.
42. Chakrabarti S, Milligan DW, Brown J, et al. Influence of cytomegalovirus (CMV) sero-positivity on CMV infection, lymphocyte recovery and non-CMV infections following T-cell-depleted allogeneic stem cell transplantation: a comparison between two T-cell depletion regimens. Bone Marrow Transplant. 2004;33:197-204.
43. Boeckh M, Nichols WG. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood. 2004;103:2003-2008.
44. Grob JP, Grundy JE, Prentice HG, et al. Immune donors can protect marrow-transplant recipients from severe cytomegalovirus infections. Lancet. 1987;1:774-776.
45. Boeckh M, Nichols WG, Papanicolaou G, et al. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant. 2003;9:543-558.
46. Lin TS, Zahrieh D, Weller E, et al. Risk factors for cytomegalovirus reactivation after CD6+ T-cell-depleted allogeneic bone marrow transplantation. Transplantation. 2002;74:49-54.
47. Hakki M, Riddell SR, Storek J, et al. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. Blood. 2003;102:3060-3067.
48. Gor D, Sabin C, Prentice HG, et al. Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease. Bone Marrow Transplant. 1998;21:597-605.